每周一次胰高血糖素样肽-1 受体激动剂阿必鲁肽与基础胰岛素联合治疗与餐时胰岛素联合基础胰岛素治疗 2 型糖尿病患者的 52 周结果。
Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks.
机构信息
Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, 61 Queen St. East #6121, Toronto, Canada, M5C 2T2.
Hospital Moinhos De Vento, Rua. Ramiro Barcelos, 910, Floresta, Porto Alegre, RS, Brazil.
出版信息
J Diabetes Complications. 2017 Aug;31(8):1283-1285. doi: 10.1016/j.jdiacomp.2017.05.010. Epub 2017 May 25.
We have previously reported that once-weekly albiglutide was noninferior to thrice-daily lispro for glycemic lowering, with decreased weight and risk of hypoglycemia, in patients inadequately controlled on basal insulin over 26 weeks. Findings after 52 weeks reveal similar responses to albiglutide as an add-on to insulin glargine.
我们之前曾报道过，在 26 周的时间里，对于基础胰岛素控制不佳的患者，每周一次的阿必鲁肽与每日三次的赖脯胰岛素相比，在降低血糖方面不劣效，且体重减轻和低血糖风险降低。52 周后的研究结果显示，阿必鲁肽作为胰岛素甘精的附加疗法，具有相似的应答效果。
Zotero 插件